VistaGen Q1 revenue rises on licensing agreement expiration - VTGN News | Rallies

VistaGen Q1 revenue rises on licensing agreement expiration

VTGN•2026-08-14

Outlook

VistaGen expects R&D expenses to decrease due to cash preservation and completed studies.
The company expects G&A expenses to remain at current levels, pending FDA feedback.
VistaGen says cash resources are expected to fund operations into 2027 but not beyond one year.

Overview

The US biopharma firm's fiscal Q1 revenue rose, driven by licensing agreement expiration.
Net loss for fiscal Q1 narrowed from the prior year as R&D and G&A expenses declined.
The company plans an FDA meeting on fasedienol and added neuroscience drug development leaders.

Result Drivers

Licensing agreement - Revenue was recognized mainly due to expiration of the exclusivity period under the Fuji Pharma agreement.
Cost management - Lower R&D and G&A expenses reflected cash preservation measures and the conclusion of key studies.

Key details and analyst coverage

Metric	Actual
Q1 Loss Per Share	$0.30
Q1 Net Loss	$13.03 mln

Related News

Nutra Pharma delays Q2 10-Q filing, citing need for more time to finalize financials

NPHC•2026-08-14

Bond Provides Business Update And Reports 2026 Second Quarter Financial Results

OBAI•2026-08-14

Nasdaq Trade Halt <SKYE.O> Halt News Pending at 09:00 AM